EIGR.Q Stock Overview
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Eiger BioPharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.19 |
| 52 Week High | US$43.35 |
| 52 Week Low | US$1.10 |
| Beta | 1.87 |
| 1 Month Change | -54.47% |
| 3 Month Change | -67.51% |
| 1 Year Change | -92.84% |
| 3 Year Change | -99.14% |
| 5 Year Change | -99.35% |
| Change since IPO | -99.54% |
Recent News & Updates
Recent updates
Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) 28% Dip In Price Shows Sentiment Is Matching Revenues
Apr 01
The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%
Jan 04Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%
Dec 20Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher
Nov 09Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt
Oct 06Eiger sheds ~20% on abandonment of EUA request for COVID therapy
Oct 05Eiger falls 21% amid uncertainty over regulatory path for COVID-19 therapy
Sep 06Eiger BioPharmaceuticals: Undervalued Biotech With End Of 2022 Catalyst
Jul 26European Commission approves Eiger BioPharmaceuticals' progeria therapy Zokinvy
Jul 20Eiger Biopharmaceuticals: Value Inflection For Lead Asset In HDV Infection On The Horizon
Apr 06Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Analysts Are More Bearish Than They Used To Be
Mar 15Eiger Pharma: HDV Approval In 2023 Is A Major Catalyst
Dec 26Shareholder Returns
| EIGR.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.8% | -4.7% | -3.7% |
| 1Y | -92.8% | -2.7% | 20.2% |
Return vs Industry: EIGR.Q underperformed the US Biotechs industry which returned -2% over the past year.
Return vs Market: EIGR.Q underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| EIGR.Q volatility | |
|---|---|
| EIGR.Q Average Weekly Movement | 29.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EIGR.Q's share price has been volatile over the past 3 months.
Volatility Over Time: EIGR.Q's weekly volatility has increased from 22% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 25 | David Apelian | www.eigerbio.com |
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company’s product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia.
Eiger BioPharmaceuticals, Inc. Fundamentals Summary
| EIGR.Q fundamental statistics | |
|---|---|
| Market cap | US$3.24m |
| Earnings (TTM) | -US$74.96m |
| Revenue (TTM) | US$15.77m |
0.2x
P/S Ratio0.0x
P/E RatioIs EIGR.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EIGR.Q income statement (TTM) | |
|---|---|
| Revenue | US$15.77m |
| Cost of Revenue | US$24.00k |
| Gross Profit | US$15.75m |
| Other Expenses | US$90.71m |
| Earnings | -US$74.96m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -50.62 |
| Gross Margin | 99.85% |
| Net Profit Margin | -475.26% |
| Debt/Equity Ratio | -284.4% |
How did EIGR.Q perform over the long term?
See historical performance and comparison